Chronic Lymphocytic Leukemia Clinical Trials in Palo Alto, California

8 studies are recruiting for chronic lymphocytic leukemia in Palo Alto, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

   This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford Cancer Institute Palo Alto, Palo Alto, California

   Locations

   632 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04269902 on ClinicalTrials.gov

2. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Medicine, Palo Alto, California

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

3. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

   The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford Cancer Institute, Palo Alto, California

   Locations

   214 in total

   Run by

   BeOne Medicines

   See if you can join NCT06973187 on ClinicalTrials.gov

4. A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

   The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocyti…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford Cancer Institute, Palo Alto, California

   Locations

   114 in total

   Run by

   BeOne Medicines

   See if you can join NCT07277231 on ClinicalTrials.gov

5. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

   The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituxi…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford Cancer Institute, Palo Alto, California

   Locations

   195 in total

   Run by

   BeOne Medicines

   See if you can join NCT06943872 on ClinicalTrials.gov

6. A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

   The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treat…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto, California

   Locations

   143 in total

   Run by

   Loxo Oncology, Inc.

   See if you can join NCT05254743 on ClinicalTrials.gov

7. A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

   The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inh…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto, California

   Locations

   131 in total

   Run by

   Loxo Oncology, Inc.

   See if you can join NCT06588478 on ClinicalTrials.gov

8. Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

   This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chronic lymphocytic leukemia or small lymphocytic ly…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Stanford Cancer Institute Palo Alto, Palo Alto, California

   Locations

   3 in total

   Run by

   Mayo Clinic

   See if you can join NCT05388006 on ClinicalTrials.gov